Do analysts prefer NNNN or TMDX?

TransMedics Group has a consensus target price of $121.10, indicating a potential upside of 40.13%. Given TransMedics Group's stronger consensus rating and higher possible upside, analysts plainly believe TransMedics Group is more favorable than Anbio Biotechnology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Anbio Biotechnology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 TransMedics Group 1 Sell rating(s) 6 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.33

Which has higher valuation & earnings, NNNN or TMDX?

TransMedics Group has higher revenue and earnings than Anbio Biotechnology. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Anbio Biotechnology $8.65M 87.33 $6.40M N/A N/A TransMedics Group $605.49M 4.93 $190.29M $3.89 22.22

Does the media prefer NNNN or TMDX?

In the previous week, TransMedics Group had 11 more articles in the media than Anbio Biotechnology. MarketBeat recorded 12 mentions for TransMedics Group and 1 mentions for Anbio Biotechnology. TransMedics Group's average media sentiment score of 0.68 beat Anbio Biotechnology's score of -0.54 indicating that TransMedics Group is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Anbio Biotechnology 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Negative TransMedics Group 3 Very Positive mention(s) 3 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend NNNN or ATRC?

AtriCure has a consensus target price of $53.30, suggesting a potential downside of 8.26%. Given AtriCure's stronger consensus rating and higher possible upside, analysts plainly believe AtriCure is more favorable than Anbio Biotechnology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Anbio Biotechnology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 AtriCure 0 Sell rating(s) 4 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 2.75

Which has preferable valuation and earnings, NNNN or ATRC?

Anbio Biotechnology has higher earnings, but lower revenue than AtriCure. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Anbio Biotechnology $8.65M 87.33 $6.40M N/A N/A AtriCure $534.53M 5.53 -$11.45M $0.21 276.67

Does the media refer more to NNNN or ATRC?

In the previous week, AtriCure had 8 more articles in the media than Anbio Biotechnology. MarketBeat recorded 9 mentions for AtriCure and 1 mentions for Anbio Biotechnology. AtriCure's average media sentiment score of 0.78 beat Anbio Biotechnology's score of -0.54 indicating that AtriCure is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Anbio Biotechnology 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Negative AtriCure 4 Very Positive mention(s) 3 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate NNNN or AXGN?

AxoGen has a consensus target price of $51.56, suggesting a potential upside of 16.56%. Given AxoGen's stronger consensus rating and higher possible upside, analysts clearly believe AxoGen is more favorable than Anbio Biotechnology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Anbio Biotechnology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 AxoGen 1 Sell rating(s) 1 Hold rating(s) 10 Buy rating(s) 0 Strong Buy rating(s) 2.75

Which has preferable valuation & earnings, NNNN or AXGN?

Anbio Biotechnology has higher earnings, but lower revenue than AxoGen. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Anbio Biotechnology $8.65M 87.33 $6.40M N/A N/A AxoGen $225.21M 10.56 -$15.70M -$0.68 N/A

Does the media refer more to NNNN or AXGN?

In the previous week, AxoGen had 1 more articles in the media than Anbio Biotechnology. MarketBeat recorded 2 mentions for AxoGen and 1 mentions for Anbio Biotechnology. AxoGen's average media sentiment score of 0.67 beat Anbio Biotechnology's score of -0.54 indicating that AxoGen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Anbio Biotechnology 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Negative AxoGen 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend ESTA or NNNN?

Establishment Labs currently has a consensus target price of $100.25, indicating a potential upside of 44.66%. Given Establishment Labs' stronger consensus rating and higher possible upside, equities research analysts plainly believe Establishment Labs is more favorable than Anbio Biotechnology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Establishment Labs 1 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.78 Anbio Biotechnology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable valuation and earnings, ESTA or NNNN?

Anbio Biotechnology has lower revenue, but higher earnings than Establishment Labs. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Establishment Labs $211.08M 9.78 -$51.06M -$1.31 N/A Anbio Biotechnology $8.65M 87.33 $6.40M N/A N/A

Does the media prefer ESTA or NNNN?

In the previous week, Establishment Labs and Establishment Labs both had 1 articles in the media. Establishment Labs' average media sentiment score of 1.67 beat Anbio Biotechnology's score of -0.54 indicating that Establishment Labs is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Establishment Labs 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Anbio Biotechnology 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Negative

Do analysts recommend NNNN or BFLY?

Butterfly Network has a consensus target price of $6.56, indicating a potential downside of 16.87%. Given Butterfly Network's stronger consensus rating and higher probable upside, analysts plainly believe Butterfly Network is more favorable than Anbio Biotechnology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Anbio Biotechnology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Butterfly Network 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.40

Which has stronger earnings and valuation, NNNN or BFLY?

Anbio Biotechnology has higher earnings, but lower revenue than Butterfly Network. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Anbio Biotechnology $8.65M 87.33 $6.40M N/A N/A Butterfly Network $97.61M 21.54 -$77.06M -$0.29 N/A

Does the media favor NNNN or BFLY?

In the previous week, Butterfly Network had 8 more articles in the media than Anbio Biotechnology. MarketBeat recorded 9 mentions for Butterfly Network and 1 mentions for Anbio Biotechnology. Butterfly Network's average media sentiment score of 0.50 beat Anbio Biotechnology's score of -0.54 indicating that Butterfly Network is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Anbio Biotechnology 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Negative Butterfly Network 2 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Anbio Biotechnology (NNNN) Competitors

$5.25 -0.35 (-6.25%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$5.46 +0.21 (+4.00%)

As of 09/18/2026 07:57 PM Eastern

Compare

NNNN vs. TMDX, ATRC, AXGN, ESTA, and BFLY

Should you buy Anbio Biotechnology stock or one of its competitors? Anbio Biotechnology's main competitors and comparable companies include TransMedics Group (TMDX), AtriCure (ATRC), AxoGen (AXGN), Establishment Labs (ESTA), and Butterfly Network (BFLY). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does Anbio Biotechnology compare to TransMedics Group?

Anbio Biotechnology (NASDAQ:NNNN) and TransMedics Group (NASDAQ:TMDX) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their media sentiment, valuation, analyst recommendations, profitability, earnings, dividends, risk and institutional ownership.

99.7% of TransMedics Group shares are owned by institutional investors. 6.9% of TransMedics Group shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

TransMedics Group has a net margin of 22.69% compared to Anbio Biotechnology's net margin of 0.00%. TransMedics Group's return on equity of 15.88% beat Anbio Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Anbio Biotechnology	N/A	N/A	N/A
TransMedics Group	22.69%	15.88%	5.95%

TransMedics Group has higher revenue and earnings than Anbio Biotechnology.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anbio Biotechnology	$8.65M	87.33	$6.40M	N/A	N/A
TransMedics Group	$605.49M	4.93	$190.29M	$3.89	22.22

In the previous week, TransMedics Group had 11 more articles in the media than Anbio Biotechnology. MarketBeat recorded 12 mentions for TransMedics Group and 1 mentions for Anbio Biotechnology. TransMedics Group's average media sentiment score of 0.68 beat Anbio Biotechnology's score of -0.54 indicating that TransMedics Group is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Anbio Biotechnology	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Negative
TransMedics Group	3 Very Positive mention(s)	3 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

TransMedics Group has a consensus target price of $121.10, indicating a potential upside of 40.13%. Given TransMedics Group's stronger consensus rating and higher possible upside, analysts plainly believe TransMedics Group is more favorable than Anbio Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anbio Biotechnology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
TransMedics Group	1 Sell rating(s)	6 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.33

Anbio Biotechnology has a beta of 5.17, indicating that its stock price is 417% more volatile than the broader market. Comparatively, TransMedics Group has a beta of 1.9, indicating that its stock price is 90% more volatile than the broader market.

Summary

TransMedics Group beats Anbio Biotechnology on 12 of the 14 factors compared between the two stocks.

How does Anbio Biotechnology compare to AtriCure?

Anbio Biotechnology (NASDAQ:NNNN) and AtriCure (NASDAQ:ATRC) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, earnings, risk, valuation, profitability, institutional ownership, dividends and analyst recommendations.

AtriCure has a net margin of 1.85% compared to Anbio Biotechnology's net margin of 0.00%. AtriCure's return on equity of 2.34% beat Anbio Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Anbio Biotechnology	N/A	N/A	N/A
AtriCure	1.85%	2.34%	1.77%

99.1% of AtriCure shares are owned by institutional investors. 4.0% of AtriCure shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Anbio Biotechnology has a beta of 5.17, suggesting that its share price is 417% more volatile than the broader market. Comparatively, AtriCure has a beta of 1.26, suggesting that its share price is 26% more volatile than the broader market.

Anbio Biotechnology has higher earnings, but lower revenue than AtriCure.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anbio Biotechnology	$8.65M	87.33	$6.40M	N/A	N/A
AtriCure	$534.53M	5.53	-$11.45M	$0.21	276.67

In the previous week, AtriCure had 8 more articles in the media than Anbio Biotechnology. MarketBeat recorded 9 mentions for AtriCure and 1 mentions for Anbio Biotechnology. AtriCure's average media sentiment score of 0.78 beat Anbio Biotechnology's score of -0.54 indicating that AtriCure is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Anbio Biotechnology	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Negative
AtriCure	4 Very Positive mention(s)	3 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

AtriCure has a consensus target price of $53.30, suggesting a potential downside of 8.26%. Given AtriCure's stronger consensus rating and higher possible upside, analysts plainly believe AtriCure is more favorable than Anbio Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anbio Biotechnology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
AtriCure	0 Sell rating(s)	4 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.75

Summary

AtriCure beats Anbio Biotechnology on 12 of the 15 factors compared between the two stocks.

How does Anbio Biotechnology compare to AxoGen?

Anbio Biotechnology (NASDAQ:NNNN) and AxoGen (NASDAQ:AXGN) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, dividends, profitability, institutional ownership, risk, analyst recommendations, earnings and media sentiment.

In the previous week, AxoGen had 1 more articles in the media than Anbio Biotechnology. MarketBeat recorded 2 mentions for AxoGen and 1 mentions for Anbio Biotechnology. AxoGen's average media sentiment score of 0.67 beat Anbio Biotechnology's score of -0.54 indicating that AxoGen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Anbio Biotechnology	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Negative
AxoGen	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Anbio Biotechnology has a beta of 5.17, meaning that its stock price is 417% more volatile than the broader market. Comparatively, AxoGen has a beta of 1.16, meaning that its stock price is 16% more volatile than the broader market.

AxoGen has a consensus target price of $51.56, suggesting a potential upside of 16.56%. Given AxoGen's stronger consensus rating and higher possible upside, analysts clearly believe AxoGen is more favorable than Anbio Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anbio Biotechnology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
AxoGen	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75

Anbio Biotechnology has higher earnings, but lower revenue than AxoGen.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anbio Biotechnology	$8.65M	87.33	$6.40M	N/A	N/A
AxoGen	$225.21M	10.56	-$15.70M	-$0.68	N/A

80.3% of AxoGen shares are owned by institutional investors. 2.4% of AxoGen shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Anbio Biotechnology has a net margin of 0.00% compared to AxoGen's net margin of -13.36%. Anbio Biotechnology's return on equity of 0.00% beat AxoGen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Anbio Biotechnology	N/A	N/A	N/A
AxoGen	-13.36%	-8.90%	-6.47%

Summary

AxoGen beats Anbio Biotechnology on 8 of the 14 factors compared between the two stocks.

How does Anbio Biotechnology compare to Establishment Labs?

Establishment Labs (NASDAQ:ESTA) and Anbio Biotechnology (NASDAQ:NNNN) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, risk, earnings, profitability, dividends, valuation, institutional ownership and media sentiment.

Establishment Labs currently has a consensus target price of $100.25, indicating a potential upside of 44.66%. Given Establishment Labs' stronger consensus rating and higher possible upside, equities research analysts plainly believe Establishment Labs is more favorable than Anbio Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Establishment Labs	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.78
Anbio Biotechnology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Establishment Labs and Establishment Labs both had 1 articles in the media. Establishment Labs' average media sentiment score of 1.67 beat Anbio Biotechnology's score of -0.54 indicating that Establishment Labs is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Establishment Labs	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Anbio Biotechnology	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Negative

Anbio Biotechnology has a net margin of 0.00% compared to Establishment Labs' net margin of -15.82%. Anbio Biotechnology's return on equity of 0.00% beat Establishment Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Establishment Labs	-15.82%	-196.69%	-10.73%
Anbio Biotechnology	N/A	N/A	N/A

72.9% of Establishment Labs shares are held by institutional investors. 10.0% of Establishment Labs shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Anbio Biotechnology has lower revenue, but higher earnings than Establishment Labs.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Establishment Labs	$211.08M	9.78	-$51.06M	-$1.31	N/A
Anbio Biotechnology	$8.65M	87.33	$6.40M	N/A	N/A

Establishment Labs has a beta of 1.05, indicating that its stock price is 5% more volatile than the broader market. Comparatively, Anbio Biotechnology has a beta of 5.17, indicating that its stock price is 417% more volatile than the broader market.

Summary

Establishment Labs beats Anbio Biotechnology on 7 of the 13 factors compared between the two stocks.

How does Anbio Biotechnology compare to Butterfly Network?

Anbio Biotechnology (NASDAQ:NNNN) and Butterfly Network (NYSE:BFLY) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, dividends, risk, institutional ownership, profitability, analyst recommendations, valuation and media sentiment.

Anbio Biotechnology has a net margin of 0.00% compared to Butterfly Network's net margin of -66.74%. Anbio Biotechnology's return on equity of 0.00% beat Butterfly Network's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Anbio Biotechnology	N/A	N/A	N/A
Butterfly Network	-66.74%	-33.99%	-22.96%

Butterfly Network has a consensus target price of $6.56, indicating a potential downside of 16.87%. Given Butterfly Network's stronger consensus rating and higher probable upside, analysts plainly believe Butterfly Network is more favorable than Anbio Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anbio Biotechnology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Butterfly Network	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

In the previous week, Butterfly Network had 8 more articles in the media than Anbio Biotechnology. MarketBeat recorded 9 mentions for Butterfly Network and 1 mentions for Anbio Biotechnology. Butterfly Network's average media sentiment score of 0.50 beat Anbio Biotechnology's score of -0.54 indicating that Butterfly Network is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Anbio Biotechnology	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Negative
Butterfly Network	2 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Anbio Biotechnology has higher earnings, but lower revenue than Butterfly Network.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anbio Biotechnology	$8.65M	87.33	$6.40M	N/A	N/A
Butterfly Network	$97.61M	21.54	-$77.06M	-$0.29	N/A

Anbio Biotechnology has a beta of 5.17, indicating that its stock price is 417% more volatile than the broader market. Comparatively, Butterfly Network has a beta of 2.08, indicating that its stock price is 108% more volatile than the broader market.

37.9% of Butterfly Network shares are owned by institutional investors. 22.0% of Butterfly Network shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Butterfly Network beats Anbio Biotechnology on 8 of the 14 factors compared between the two stocks.

Get Anbio Biotechnology News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NNNN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NNNN vs. The Competition

Export

Metric	Anbio Biotechnology	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$805.79M	$5.54B	$7.26B	$13.13B
Dividend Yield	N/A	1.79%	2.56%	12.94%
P/E Ratio	N/A	25.10	273.80	25.39
Price / Sales	87.33	72.24	692.79	108.43
Price / Cash	125.83	32.72	77.42	51.66
Price / Book	25.00	5.74	10.45	6.33
Net Income	$6.40M	$151.55M	$3.48B	$358.24M
7 Day Performance	-17.19%	0.67%	0.88%	1.17%
1 Month Performance	-32.26%	-3.83%	-1.58%	-2.59%
1 Year Performance	N/A	6.86%	18.09%	5.97%

Anbio Biotechnology Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NNNN Anbio Biotechnology	0.2762 of 5 stars	$5.25 -6.3%	N/A	N/A	$805.79M	$8.65M	N/A	27
TMDX TransMedics Group	4.4725 of 5 stars	$86.43 -2.1%	$124.18 +43.7%	-28.6%	$2.99B	$668.47M	22.27	210
ATRC AtriCure	2.2683 of 5 stars	$53.01 -1.3%	$52.00 -1.9%	+58.5%	$2.70B	$569.62M	252.65	1,300	Analyst Forecast
AXGN AxoGen	2.3143 of 5 stars	$47.78 +2.3%	$51.56 +7.9%	+156.3%	$2.57B	$225.21M	N/A	450
ESTA Establishment Labs	2.8584 of 5 stars	$74.80 -0.7%	$100.25 +34.0%	+70.9%	$2.23B	$245.82M	N/A	1,004	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NNNN) was last updated on 9/19/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Anbio Biotechnology (NNNN) Competitors

NNNN vs. TMDX, ATRC, AXGN, ESTA, and BFLY

How does Anbio Biotechnology compare to TransMedics Group?

Summary

How does Anbio Biotechnology compare to AtriCure?

Summary

How does Anbio Biotechnology compare to AxoGen?

Summary

How does Anbio Biotechnology compare to Establishment Labs?

Summary

How does Anbio Biotechnology compare to Butterfly Network?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NNNN vs. The Competition

Anbio Biotechnology Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Anbio Biotechnology (NNNN) Competitors

NNNN vs. TMDX, ATRC, AXGN, ESTA, and BFLY

How does Anbio Biotechnology compare to TransMedics Group?

Do institutionals & insiders have more ownership in NNNN or TMDX?

Is NNNN or TMDX more profitable?

Which has higher valuation & earnings, NNNN or TMDX?

Does the media prefer NNNN or TMDX?

Do analysts prefer NNNN or TMDX?

Which has more risk and volatility, NNNN or TMDX?

Summary

How does Anbio Biotechnology compare to AtriCure?

Is NNNN or ATRC more profitable?

Do institutionals and insiders hold more shares of NNNN or ATRC?

Which has more volatility and risk, NNNN or ATRC?

Which has preferable valuation and earnings, NNNN or ATRC?

Does the media refer more to NNNN or ATRC?

Do analysts recommend NNNN or ATRC?

Summary

How does Anbio Biotechnology compare to AxoGen?

Does the media refer more to NNNN or AXGN?

Which has more risk and volatility, NNNN or AXGN?

Do analysts rate NNNN or AXGN?

Which has preferable valuation & earnings, NNNN or AXGN?

Do insiders & institutionals hold more shares of NNNN or AXGN?

Is NNNN or AXGN more profitable?

Summary

How does Anbio Biotechnology compare to Establishment Labs?

Do analysts recommend ESTA or NNNN?

Does the media prefer ESTA or NNNN?

Is ESTA or NNNN more profitable?

Do institutionals and insiders have more ownership in ESTA or NNNN?

Which has preferable valuation and earnings, ESTA or NNNN?

Which has more volatility and risk, ESTA or NNNN?

Summary

How does Anbio Biotechnology compare to Butterfly Network?

Is NNNN or BFLY more profitable?

Do analysts recommend NNNN or BFLY?

Does the media favor NNNN or BFLY?

Which has stronger earnings and valuation, NNNN or BFLY?

Which has more risk & volatility, NNNN or BFLY?

Do insiders and institutionals believe in NNNN or BFLY?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NNNN vs. The Competition

Anbio Biotechnology Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools